In this study, we used an A2AR KO mouse model and caffeine, a non-selective antagonist of A2AR, to evaluate whether A2AR inactivation can attenuate the level of tau phosphorylation and alleviate cognitive impairment, as well as other types of neuropathological changes, at the chronic phase after TBI. This evidence concerns the gene MAPT and Cognitive impairment.